Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2025 that were previously approved by the Compensation ...
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...
Sarepta price target lowered to $179 from $210 at BofA
BofA lowered the firm’s price target on Sarepta (SRPT) to $179 from $210 and keeps a Buy rating on the shares. Following the news of the ...
Barchart on MSN19h
Global Equity Markets Slide on US Tariff Concerns
The S&P 500 Index ($SPX) (SPY) today is down -1.54%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -1.00%, and the ...
Vaccine, gene therapy makers fall after Peter Marks resignation
Novavax (NVAX), and BioNTech (BNTX) (BTNX), and gene therapy developers, including Sarepta (SRPT), Solid Biosciences (SLDB), Taysha Gene Therapies (TSHA), Capricor Therapeutics (CAPR), and Crispr ...
Moderna (NASDAQ:MRNA) Leads U.S. Biotechs’ Plunge after FDA’s Top Vaccine Regulator Resigns
Shares of some U.S. biotechnology companies including Moderna (MRNA) plunged on Monday after reports that the top vaccine official at the U.S.
RBC downgrades Sarepta on ‘less bullish’ stance after doctor checks
RBC Capital analyst Brian Abrahams downgraded Sarepta (SRPT) to Sector Perform from Outperform with a price target of $87, down from $161. The ...